Pra Health Sciences, Inc. (PRAH): Linda Baddour , Executive VP & CFO of Pra Health Sciences, Inc. sold 92,308 shares on May 6, 2016. The Insider selling transaction was reported by the company on May 10, 2016 to the Securities and Exchange Commission. The shares were sold at $46.70 per share for a total value of $4,310,783.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 10, 2016, Linda Baddour (Executive VP & CFO) sold 93,000 shares at $42.26 per share price.On Mar 10, 2016, Colin Shannon (President & CEO) sold 77,019 shares at $42.26 per share price.
PRA Health Sciences Inc: On Friday, May 6, 2016 heightened volatility was witnessed in PRA Health Sciences Inc which led to swings in the share price. The shares opened for trading at $45.22 and hit $46.19 on the upside , eventually ending the session at $45.74, with a gain of 0.37% or 0.17 points. The heightened volatility saw the trading volume jump to 4,46,286 shares. The 52-week high of the share price is $51.35 and the company has a market cap of $2,770 M . The 52-week low of the share price is at $28.372.
Company has been under the radar of several Street Analysts.PRA Health Sciences Inc is Upgraded by Citigroup to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 4, 2016.PRA Health Sciences Inc is Upgraded by Sun Trust Rbsn Humphrey to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Mar 28, 2016.
PRA Health Sciences Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development including oncology central nervous system inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services which includes Phase IIb through III product registration trials and Phase IV trials inclusive of post-marketing commitments and registries; Strategic Solutions which provides Embedded Solutions and functional outsourcing services and Early Development Services which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.